Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing
Key Highlights
- ➤Nexalin (NXL) regained Nasdaq minimum bid-price compliance after 21 consecutive trading days above $1.00.
- ➤Nasdaq granted continued listing, requiring $2.5 million stockholders’ equity compliance by January 4, 2027.
- ➤Nexalin announced a Brazil and six additional South American markets distribution agreement.
- ➤Nexalin continues pivotal HALO Clarity insomnia trial while pursuing U.S. FDA marketing authorization.
Expert Statements
Mark White, Chief Executive Officer of Nexalin
“We appreciate the Panel’s decision and are pleased to have satisfied the bid price requirement”
HOUSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has received written confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Nasdaq confirmed that the closing bid price of the Company’s common stock was above the $1.00 per share minimum for 21 consecutive trading days, from August 31 through September 29, 2026, following the Company’s previously announced reverse stock split.
The confirmation, dated September 30, 2026, follows a decision by the Nasdaq Hearings Panel (the “Panel”), dated September 25, 2026, granting the Company’s request for continued listing on Nasdaq. Under the terms of the Panel’s decision, the Company was required to demonstrate compliance with the bid price requirement, which it has now satisfied, and must demonstrate compliance with the minimum $2.5 million stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) on or before January 4, 2027.
Get started
Create a free account to read the full story.